Le Lézard
Classified in: Health
Subjects: TDS, FVT

Bridge to Life Announces Abstract Presentations at The European Society for Transplantation's ELITA Summit 2024 in Madrid, Spain, April 18-20, 2024


CHICAGO, April 2, 2024 /PRNewswire/ -- Bridge to Life Ltd, a renowned market leader in organ preservation solutions, today announced the presentation of two accepted abstracts at the 2024 ELITA Summit under the auspices of The European Society for Transplantation. The conference is scheduled to take place in Madrid, Spain, from April 18-20, 2024.

Abstracts to highlight hypothermic oxygenated perfusion in liver transplants and use in Extended Criteria Grafts

Abstracts to be presented:

100 Hypothermic Oxygenated Perfusion liver transplants in a Portuguese Centre, Júlio Constantino, MD et al, to be presented by Dulce Diogo, MD, Unidade de Transplantação Hepática de Adultos - Serviço de Cirurgia Geral, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; Poster viewing session on Thursday 18 April 2024, 19:00 ? 20:30.

Single center evolution of DCD donor utilization for liver transplantation: from perceived marginality to routine and beyond, Matteo Ravaioli, MD et al, Hepatobiliary and Transplant Surgery, Policlinico Sant'Orsola ? IRCCS Azienda Ospedaliero, Universitaria di Bologna, Bologna, Italy; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna (Italy), Bologna, Italy; Poster viewing session on Friday 19 April 2024, 12:45 - 13:45.

About Bridge to Life Ltd

Bridge to Life Ltd is a market leader in organ preservation solutions, offering premier products such as Belzer UW, EasiSlush and the VitaSmart1 hypothermic oxygenated perfusion system.  With a strong focus on product quality, innovation and accessibility, the company serves and partners with leading Transplant Centers and Organ Procurement Offices (OPO) globally.

1 VitaSmart is CE Marked and available for sale in several markets outside of the United States. VitaSmart is not approved for sale in the US. The company successfully completed its pivotal, multicenter, randomized clinical study in the US in 2023 and expects to submit its Premarket Approval submission to FDA later this year.     

SOURCE Bridge to Life, Ltd.


These press releases may also interest you

at 07:05
Mirum Pharmaceuticals, Inc. today announced data presented during the 56th European Society for Paediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting which took place this week in Milan, Italy. Data from LIVMARLI®...

at 07:00
Mallinckrodt plc, a global specialty pharmaceutical company, today announced the presentation of two posters on TERLIVAZ® (terlipressin) for injection in patients with hepatorenal syndrome (HRS) with rapid reduction in kidney function1 at the 2024...

17 mai 2024
Family Braces, Calgary's largest group of orthodontists with five locations across the city, reports a strong start to the second quarter of 2024. This positive momentum builds on the group's successful first quarter, underlining its...

17 mai 2024
American Skin Association (ASA) announced the recipients of the 2024 Inaugural Founders Award and the 2024 Research Achievement Awards at the 2024 Society for Investigative Dermatology (SID) Annual Meeting. ...

17 mai 2024
The Honourable Seamus O'Regan Jr., Minister of Labour and Seniors, on behalf of the Honourable Mark Holland, Canada's Minister of Health, and the Honourable Tom Osborne, Newfoundland and Labrador's Minister of Health and Community Services will make...

17 mai 2024
MOJO Health is excited to announce the unveiling of its revolutionary Health Care Registry ? a new in-kind tool designed to empower individuals to actively contribute to the well-being of their loved ones facing cancer and other serious diagnoses...



News published on and distributed by: